News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Bishal Gyawali: A pseudo-innovation for which you get to pay more without any added benefits
Photo of Bishal Gyawali taken from qcri.queensu.ca
Feb 14, 2024, 19:39

Bishal Gyawali: A pseudo-innovation for which you get to pay more without any added benefits

Bishal Gyawali, Associate Professor and Medical Oncologist at 

“Read the news that NALIRIFOX got approved today by the FDA. Don’t be misled to believe that this represents any innovation. This is a pseudo-innovation for which you get to pay more without any added benefits. We discuss this and other pancreatic cancer treatments in our recent The Lancet Oncology essay.”

Proceed to the essay.
Source: Bishal Gyawali/X

Bishal Gyawali cancer FDA NALIRIFOX OncoDaily Oncology Pancreatic Cancer pancreatic cancer treatment Queen’s University The Lancet Oncology
Special Coverage
Insight
Aug 13, 2025, 16:18
Udhayvir Grewal: NANETS Guidelines on Management of NEC - A Very Tough-to-Treat Disease
Science
Aug 13, 2025, 16:16
Framework to Select Multi-Cancer Detection Assays for the Vanguard Study - NCI Division of Cancer Prevention
Science
Aug 13, 2025, 15:55
Francesco Massari: Words of Wisdom about nccRCC in European Urology
Science
Aug 13, 2025, 15:48
Myeloma Paper of the Day, August 13th, Suggested by Robert Orlowski
Insight
Aug 13, 2025, 15:36
Dora Vallejo-Ardila: Highlights from First Day of MOGA 2025
Voices
Aug 13, 2025, 15:34
Sameer Keole: Privilege of Being ASTRO President Is Meeting Talented People I’d Not Met Otherwise
Voices
Aug 13, 2025, 15:32
Diana Adams: Medical Oncology Group of Australia (MOGA)⁩ Session on Increasing Workforce Pressure
Voices
Aug 13, 2025, 15:30
Proud to be No.1 in Hypertension and No.6 in Cardiology Worldwide - Servier
Voices
Aug 13, 2025, 15:29
Stefano Magno: Integrative Oncology Teams to Bridge Oncology and Primary Care
Science
Aug 13, 2025, 15:26
Arndt Vogel: Interesting Analysis on Potential Biomarkers to Guide Adjuvant Treatment
Voices
Aug 13, 2025, 15:25
Yvonne Diaz: Survival Rates for the Deadliest Cancers
Insight
Aug 13, 2025, 15:20
Amol Akhade: KEYNOTE-905 - Potential Practice Changer in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer